Special Issue

Emerging Trends in Diagnosis for COVID-19

Message from the Guest Editor

The COVID-19 pandemic has caused high number of fatalities as well as economic and societal impacts. For a prompt return to previous levels of social interaction and business, virus spread must be kept under control; to achieve this, the development of new approaches for virus testing will be centralized. Diagnostic screening should be performed at mass scale and repeated over time. Different types of diagnostic tests are now available, with alternative methods and benefits. As monitoring capacity is limited, there is a demand for new strategies that could greatly increase laboratory efficiency while maintaining the benefits of time and cost effectiveness. This Special Issue aims to focus on the increasing need for multidisciplinary approaches in which clinical and diagnostic concerns and insights incorporate to develop new efficient surveillance strategies, tailored to the characteristics of different monitoring contexts.

Guest Editor

Dr. Chia-Yu Chi

Division of Clinical Research, National Health Research Institutes, Miaoli, Taiwan

Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/128365

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).